HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) major shareholder Life Sciences X. L.P. Frazier purchased 8,850 shares of the firm's stock in a transaction that occurred on Thursday, April 4th. The stock was purchased at an average price of $14.50 per share, with a total value of $128,325.00. Following the purchase, the insider now directly owns 8,544,187 shares of the company's stock, valued at $123,890,711.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
HilleVax Stock Performance
NASDAQ:HLVX traded down $0.20 during midday trading on Monday, reaching $14.32. The stock had a trading volume of 43,077 shares, compared to its average volume of 124,483. The stock has a market cap of $711.70 million, a P/E ratio of -4.71 and a beta of 0.65. The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10. HilleVax, Inc. has a 12-month low of $9.94 and a 12-month high of $20.22. The firm has a fifty day simple moving average of $16.23 and a two-hundred day simple moving average of $14.61.
Institutional Trading of HilleVax
Several hedge funds and other institutional investors have recently made changes to their positions in HLVX. JPMorgan Chase & Co. acquired a new stake in HilleVax in the second quarter valued at about $76,000. Rhumbline Advisers acquired a new stake in shares of HilleVax in the 2nd quarter valued at approximately $187,000. Northern Trust Corp purchased a new stake in shares of HilleVax in the second quarter valued at approximately $1,145,000. American International Group Inc. acquired a new position in HilleVax during the second quarter worth $66,000. Finally, Millennium Management LLC purchased a new position in HilleVax in the second quarter worth $185,000. Hedge funds and other institutional investors own 86.42% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and issued a $28.00 target price on shares of HilleVax in a report on Thursday, March 21st.
Check Out Our Latest Research Report on HilleVax
About HilleVax
(
Get Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Read More
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
